Isconova initiates collaboration with NPO Narvac (”Narvac”) – one of Russia’s leading companies within veterinary medicine. Initially, the aim is to develop a rabies vaccine for dog and cat for the Russian market. Isconova will own all clinical data and in addition own the commercial rights for the vaccines throughout the rest of the world, except for China, where Isconova and Narvac will co-operate through a joint venture.
The agreement includes the use of Isconova’s adjuvants for developing more efficient veterinary vaccines. The first product is a Matrix M™ based rabies vaccine for dog and cat – a therapeutic area with great demand. Isconovas Matrix M™ is an adjuvant designed to stimulate the immune system and improve the effect and duration of vaccines. 

”We will build commercial success by offering top quality adjuvants and run our own vaccine projects within large therapeutic areas. Thereby, the Narvac co-operation is an important step for us where we will own the...